Goodbye, Lipitor. Pfizer Bids a Farewell

Farewell after all, Lipitor. Pfizer conducted an intriguing experiment in brand marketing this year, aggressively pushing the cholesterol-fighting drug Lipitor in the U.S. even after its patent expired on Nov. 30.
The Wall Street Journal